{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Schultz CW"],"funding":["Intramural NIH HHS","NIH NIGMS","OHSU Knight Cancer Institute","NCI NIH HHS","NCI–CCR Intramural support","NIGMS NIH HHS","NCI NIH"],"pagination":["2166-2176"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8859979"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(11)"],"pubmed_abstract":["Pancreatic ductal adenocarcinoma (PDAC) is a lethal aggressive cancer, in part due to elements of the microenvironment (hypoxia, hypoglycemia) that cause metabolic network alterations. The FDA-approved antihelminthic pyrvinium pamoate (PP) has previously been shown to cause PDAC cell death, although the mechanism has not been fully determined. We demonstrated that PP effectively inhibited PDAC cell viability with nanomolar IC50 values (9-93 nmol/L) against a panel of PDAC, patient-derived, and murine organoid cell lines. <i>In vivo</i>, we demonstrated that PP inhibited PDAC xenograft tumor growth with both intraperitoneal (IP; <i>P</i> < 0.0001) and oral administration (PO; <i>P</i> = 0.0023) of human-grade drug. Metabolomic and phosphoproteomic data identified that PP potently inhibited "],"journal":["Molecular cancer therapeutics"],"pubmed_title":["The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria."],"pmcid":["PMC8859979"],"funding_grant_id":["R01 CA243445","P30 CA010815","P30 CA056036","P50 CA127297","R01 CA212600","U01 CA224012","R01 CA216853","U01CA224012","P01 CA217798","R01 CA163649","R01CA216853","P30CA056036","P30 CA069533","P01CA217798","T32 GM008562","T32GM008562","Z01 006150","R01CA212600-01","Z01 BC006150","R01CA243445","P50CA127297"],"pubmed_authors":["Schultz CW","Cassel J","Calvert VS","Yeo CJ","McCarthy GA","Wang D","McCoy MD","DuHadaway JB","Brown SZ","Goetz A","Nerwal T","Shaghaghi H","Prendergast GC","Jain A","Jiang W","Pishvaian MJ","Dixon DA","Preet R","Petricoin EF","Singh PK","Brody JR","Golan T","Salvino J","Summer R","Pommier Y","Nevler A","Baechler SA","Vishwakarma V"],"additional_accession":[]},"is_claimable":false,"name":"The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria.","description":"Pancreatic ductal adenocarcinoma (PDAC) is a lethal aggressive cancer, in part due to elements of the microenvironment (hypoxia, hypoglycemia) that cause metabolic network alterations. The FDA-approved antihelminthic pyrvinium pamoate (PP) has previously been shown to cause PDAC cell death, although the mechanism has not been fully determined. We demonstrated that PP effectively inhibited PDAC cell viability with nanomolar IC50 values (9-93 nmol/L) against a panel of PDAC, patient-derived, and murine organoid cell lines. <i>In vivo</i>, we demonstrated that PP inhibited PDAC xenograft tumor growth with both intraperitoneal (IP; <i>P</i> < 0.0001) and oral administration (PO; <i>P</i> = 0.0023) of human-grade drug. Metabolomic and phosphoproteomic data identified that PP potently inhibited ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2025-04-25T22:59:19.502Z","creation":"2025-04-06T09:13:15.347Z"},"accession":"S-EPMC8859979","cross_references":{"pubmed":["34413127"],"doi":["10.1158/1535-7163.mct-20-0652","10.1158/1535-7163.MCT-20-0652"]}}